Nov 7, 2025
Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01
Mads Kronborg
Vice President, Investor Relations & Communication
Email: mak@evaxion.ai
Telephone: +45 53 54 82 96
For general investor relations inquiries please use the contact form below